Vogt Frederick G 4

What Happened

• Frederick G. Vogt, Interim CEO & General Counsel and a director of Iovance Biotherapeutics (IOVA), had restricted stock units (RSUs) vest on June 5, 2026. A total of 31,250 RSUs converted into common stock (reported as derivative exercises, code M) at an acquisition price of $0.00 per share.
• To satisfy mandatory tax withholding, 6,638 shares were withheld (code F) at a withholding price of $4.23 per share, totaling $28,079. After withholding, Vogt received a net 24,612 shares added to his holdings. The withholding was not an open-market sale.

Key Details

• Transaction date: 2026-06-05; Form 4 filed 2026-06-09 (timely within the two-business-day reporting window).
• Conversion: 31,250 RSUs -> 31,250 shares (reported as two M entries of 15,625 each).
• Tax withholding: 6,638 shares withheld at $4.23/share = $28,079 (reported as F; not an open-market sale).
• Net shares received: 31,250 − 6,638 = 24,612 shares.
• Footnotes: RSUs vested on the transaction date; each RSU converts to one share. Withheld shares satisfy mandatory tax withholding (not a sale). Remaining RSUs from the March 5, 2025 grant will continue to vest in equal quarterly installments.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• This transaction reflects RSU vesting and conversion to common stock (an award vesting), not a market purchase or sale. The withholding to cover taxes is routine and does not indicate an open-market sale of shares.